Drug search by name

InnoPran XL and Saquinavir

Determining the interaction of InnoPran XL and Saquinavir and the possibility of their joint administration.

Check result:

InnoPran XL <> Saquinavir

Relevance: 11.01.2023 Reviewer: Shkutko P.M., M.D., in

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Consumer:

Using saquinavir together with propranolol is not recommended. Combining these medications can increase the risk of an irregular heart rhythm that may be serious. You should seek immediate medical attention if you develop sudden dizziness, lightheadedness, fainting, slow pulse, or irregular heartbeat during treatment with these medications, whether together or alone. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Professional:

GENERALLY AVOID: Saquinavir in combination with ritonavir has been shown to prolong the PR interval of the electrocardiogram in some patients. Theoretically, coadministration with other agents that prolong the PR interval (e.g., beta blockers, digoxin, diltiazem, lacosamide, mefloquine, verapamil) may result in additive effects and increased risk of bradycardia and heart block. In a study of 59 healthy volunteers aged 18 to 55 years, PR interval prolongation greater than 200 msec (first-degree atrioventricular block) was observed on treatment day 3 in 40% and 47% of subjects during administration of saquinavir/ritonavir at a therapeutic dosage of 1000 mg/100 mg twice daily and a supratherapeutic dosage of 1500 mg/100 mg twice daily, respectively, compared to 3% of subjects during administration of the active control (moxifloxacin) and 5% of subjects during administration of placebo. The maximum mean PR interval changes relative to the predose baseline value were 25 msec and 34 msec for the saquinavir/ritonavir therapeutic and supratherapeutic regimens, respectively, while almost no change occurred during the moxifloxacin and placebo arms.

MANAGEMENT: Ritonavir-boosted saquinavir should not be used with other agents that prolong the PR interval.

References

"Product Information. Invirase (saquinavir)." Roche Laboratories, Nutley, NJ.
FDA. U.S. Food and Drug Administration "FDA drug safety communication: Ongoing safety review of Invirase (saquinavir) and possible association with abnormal heart rhythms. Available from: URL: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm201221.h" ([2010 Feb 23]):
Biondi L "Health Canada endorsed important safety information on Invirase (saquinavir mesylate). Available from: URL: http://hc-sc.gc.ca/dhp-mps/alt_formats/pdf/medeff/advisories-avis/prof/2010/invirase_hpc-cps-eng.pdf." ([2010 Apr 14]):

InnoPran XL

Generic Name: propranolol

Brand name: Hemangeol, Inderal LA, Inderal XL, InnoPran XL, Inderal, InnoPran XL

Synonyms: n.a.

What is InnoPran XL?

Saquinavir

Generic Name: saquinavir

Brand name: Invirase, Fortovase

Synonyms: n.a.

What is Saquinavir?

+ Add a drug Remove all

In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.

The list of popular interactions